Castle Biosciences, Inc. - Common stock · Transaction Mar 15, 2022 · Filed Apr 17, 2022 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · CSTL
+0.00% · +$0.0000 · Vol Not reported
Market closed · last close shown
Castle Biosciences Inc
Health Care
$29.95
Veridion Score
BETAHIGH CONF · 6/6 factorsMon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET · CSTL
MethodologyCSTL
Castle Biosciences Inc
Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
STRONG
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
79/ 100
Veridion Score
STRONG · HIGH confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6/6 factors with data · Mon Aug 17 · last completed session · Pre-market · regular session opens 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is CSTL moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Castle Biosciences Inc
SERVICES-MEDICAL LABORATORIESListed since
2019
Employees
1K
Country
US
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$29.95
Last session
Day high
$29.95
Last session
Day low
$29.95
Last session
Previous close
$29.95
52W high
$43.04
-30.41% from high
52W low
$18.15
47% of range
Market cap
$904.9M
EPS
$-0.4300
Beta
1.09
Shares out
30.5M
Avg volume
429K
VWAP
$29.95
Last session
Price history computed in-house
1W
-7.10%
1M
+23.97%
3M
+49.53%
1Y
+45.67%
YTD
-23.01%
SMA 50 $24.93 · above
SMA 200 $29.29 · above
52W position 47%
CSTL overview
Related filings and maps
Public disclosures
Congress activity in CSTL
Official filing ↗
CSTL · Transaction Dec 23, 2020 · Filed Jan 11, 2021 · $1,001 to $15,000
Castle biosciences, Inc. - Common stock · Transaction Dec 21, 2020 · Filed Jan 7, 2021 · $1,001 to $15,000
Federal contracts
CSTL contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CSTL in this window.
Lobbying spend
CSTL lobbying filings, year to date.
Registered lobbying filings matched to Castle Biosciences Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CSTL in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for CSTL.
Options
Sovereign unlock shows live options positioning for CSTL.